Clinical Trials

At Texas Heart Institute
Texas Heart Institute App Clinical Research
Menu
Current Clinical Trials

CENTER FOR CLINICAL RESEARCH

Texas Heart Institute researchers conduct clinical trials to test the safety and efficacy of potential new devices, techniques and therapies to treat patients suffering from various cardiovascular issues.

Contact Us

ACTIVE-3 TICO Trial (NCT04501978)

Therapeutics for Inpatients with COVID-19

ALIVE Trial (NCT02931240)

Clinical Study of the BioVentrix Revivent System for Treatment of Left Ventricular Aneurysms (ALIVE)

ANTHEM-HFrEF Pivotal Study (NCT03425422)

Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure with Reduced Ejection Fraction

CardiAMP™ Heart Failure Trial (NCT02438306)

A clinical trial for patients suffering from heart failure due to a previous heart attack.

Catch HF

Characterization of Ambulatory NT-proBNP Cut-offs for Patients Possibly Having Heart Failure: CATCH-HF

CHIEF HF Study (NCT04252287)

Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure

The EXACT Trial (NCT04125732)

Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment

The Global cVAD Study (NCT04136392)

The Global cVAD Study will utilize observational data of the ABIOMED, Inc. hemodynamic support devices in real-world settings to drive best practice usage patterns identified through study analysis, to serve as a tool to measure and improve the quality of patient care, and also serve as a resource for future research and regulatory filings.

DCM II TRIAL (NCT04476901)

A Phase IIB randomized, placebo-controlled, multicenter study of the comparative efficacy and safety of transendocardial injection of allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy NIDCM.

GORE EXCLUDER (NCT02489539)

Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

Heart FID (NCT03037931)

Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency

Houston HeartReach

The Houston HeartReach Registry is a community-wide registry research study that aims to make improvements in heart disease prevention, diagnosis, and treatment for all women to help identify trends in heart-health risks in a diverse population of women, develop future clinical trials, and recruit women for future research studies.

LA PACING

A study evaluating the efficacy of smaller internal shocks in converting Atrial Fibrillation to normal sinus rhythm in patients undergoing a clinically indicated ablation procedure to avoid unpleasant and potentially painful external shocks, which would otherwise be routinely required.

LESS-VT (NCT03490201)

A clinical investigation to demonstrate the safety and effectiveness of ventricular ablation therapy using the FlexAbility Sensor Enabled Ablation Catheter in patients with drug-refractory monomorphic ventricular tachycardia in whom ventricular tachycardia recurs despite antiarrhythmic drug therapy or when antiarrhythmic drugs are not tolerated or desired.

OPTIMIZE (NCT03190473)

The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study

PERFORMANCE II Study (NCT04201132)

An open label study to evaluate the safety and effectiveness of the Neuroguard IEP System for the treatment of carotid artery stenosis in patients at elevated risk for adverse events following carotid endarterectomy (CEA).

PORTICO IDE (NCT02000115)

The PORTICO clinical trial is a prospective, multi-center, randomized, controlled clinical study, designed to evaluate the safety and effectiveness of the Portico Transcatheter Heart Valve and Delivery Systems via transfemoral and alternative delivery methods.

Solve CRT (NCT02922036)

Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients

Stem Cell Therapy vs Standard of Care in Cardiomyopathy (NCT02962661)

Randomized 3-Arm Trial with Standard of Care Alone vs either Intravenous Infusion or Transendocardial Injection of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) plus Standard of Care in Patients with Anthracycline-Associated Cardiomyopathy